HealthQuill ENaBL platform
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.
Pharma

AstraZeneca acquires EsoBiotec for $1billion in a bid to push its cell therapy agenda

HQ Team March 17, 2025: AstraZeneca has announced plans to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies, for up to.

Read More